XML 54 R43.htm IDEA: XBRL DOCUMENT v3.25.4
STOCKHOLDERS' EQUITY (Details)
 12 Months Ended
Oct. 07, 2025
USD ($)
item
$ / shares
shares
Jul. 02, 2025
USD ($)
$ / shares
shares
Jun. 24, 2025
Jun. 23, 2025
Jun. 18, 2025
Jun. 06, 2025
USD ($)
$ / shares
shares
Jul. 21, 2024
USD ($)
D
$ / shares
shares
Sep. 08, 2023
USD ($)
$ / shares
shares
Dec. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Jul. 31, 2025
shares
Oct. 25, 2022
$ / shares
shares
STOCKHOLDERS' EQUITY                        
Reverse stock split ratio     0.033   0.033              
Warrants issued to purchase shares                 3,032,892      
Proceeds from exercise of warrants | $                 $ 7,243,143 $ 61,410,815    
Warrant liability | $                 226,000 1,718,000    
Fair value of the warrants allocated to preferred stock | $                 5,788,380      
Exercise of warrants into common shares | $                 $ 7,981,437 $ 2,298,143    
Common stock par value | $ / shares                 $ 0.00001 $ 0.00001    
Public offering                        
STOCKHOLDERS' EQUITY                        
Gross proceeds from stockholders' equity | $   $ 6,900,000                    
September 2023 Private Placement                        
STOCKHOLDERS' EQUITY                        
Gross proceeds | $               $ 14,652,000,000        
Net proceeds | $               $ 815,000,000        
October 2022 Public Offering and Private Placement                        
STOCKHOLDERS' EQUITY                        
Warrants issued to purchase shares                       75,939
Exercise price of warrants (in dollars per share) | $ / shares                       $ 58.8
Common Stock [Member]                        
STOCKHOLDERS' EQUITY                        
Shares issued                 1,045,000      
Fair value of the warrants allocated to preferred stock | $                 $ 11      
Exercise of warrants into common shares (in shares)                 1,659,138 18,239    
Exercise of warrants into common shares | $                 $ 16      
Minimum                        
STOCKHOLDERS' EQUITY                        
Reverse stock split ratio       0.10                
Maximum                        
STOCKHOLDERS' EQUITY                        
Reverse stock split ratio       0.033                
Class A Units | Public offering                        
STOCKHOLDERS' EQUITY                        
Number of units issued   1,045,000                    
Number of shares in a unit   1                    
Price per unit | $ / shares   $ 5                    
Class A Units | Over allotment option                        
STOCKHOLDERS' EQUITY                        
Number of units issued   180,000                    
Class B Unit | Public offering                        
STOCKHOLDERS' EQUITY                        
Number of units issued   335,000                    
Price per unit | $ / shares   $ 4.99999                    
Series E-1 preferred stock | September 2023 Private Placement                        
STOCKHOLDERS' EQUITY                        
Conversion price per share | $ / shares               $ 35.6        
Shares issued               1,225        
Series E-2 Preferred Stock                        
STOCKHOLDERS' EQUITY                        
Preferred stock, share outstanding                 35.6 35.6    
Series E-2 Preferred Stock | Common Stock [Member]                        
STOCKHOLDERS' EQUITY                        
Conversion of preferred shares into common shares (in shares)                   104,088    
Series E-3 preferred stock | Common Stock [Member]                        
STOCKHOLDERS' EQUITY                        
Conversion of preferred shares into common shares (in shares)                   461,538    
Series E-4 preferred stock                        
STOCKHOLDERS' EQUITY                        
Fair value of the warrants allocated to preferred stock | $                   $ 15,914,632    
Series E-4 preferred stock | Common Stock [Member]                        
STOCKHOLDERS' EQUITY                        
Conversion of preferred shares into common shares (in shares)                   224,664    
Common warrant | Public offering                        
STOCKHOLDERS' EQUITY                        
Warrants term   5 years                    
Exercise price of warrants (in dollars per share) | $ / shares   $ 5.25                    
Common warrant | Class A Units | Public offering                        
STOCKHOLDERS' EQUITY                        
Number of warrants in a unit   1                    
Number of share of common stock per warrant   1                    
Common warrant | Class B Unit | Public offering                        
STOCKHOLDERS' EQUITY                        
Number of warrants in a unit   1                    
Prefunded Warrant | Class B Unit | Public offering                        
STOCKHOLDERS' EQUITY                        
Number of warrants in a unit   1                    
Number of share of common stock per warrant   1                    
October 2025 Warrant Inducement                        
STOCKHOLDERS' EQUITY                        
Warrants issued to purchase shares 1,048,094                      
Exercise price of warrants (in dollars per share) | $ / shares $ 5.25                      
Price per share | $ / shares 6                      
Price per warrant | $ / shares $ 0.125                      
Number of warrants issued | item 2                      
Price paid per warrant | $ / shares $ 0.125                      
Proceeds from issuance and exercise of warrants | $ $ 5,800,000                      
June 2025 Warrant Inducement                        
STOCKHOLDERS' EQUITY                        
Warrants issued to purchase shares           276,044            
Exercise price of warrants (in dollars per share) | $ / shares           $ 9.123            
Proceeds from exercise of warrants | $           $ 2,500,000            
2023 Tranche A Preferred Warrants | Series E-3 preferred stock | September 2023 Private Placement                        
STOCKHOLDERS' EQUITY                        
Warrants issued to purchase shares               2,205        
2023 Tranche B Preferred Warrants                        
STOCKHOLDERS' EQUITY                        
Warrants issued to purchase shares                 14,652      
Exercise price of warrants (in dollars per share) | $ / shares                 $ 143.25      
Warrants outstanding                     105  
2023 Tranche B Preferred Warrants | Series E-4 preferred stock                        
STOCKHOLDERS' EQUITY                        
Warrants issued to purchase shares             1,610          
Preferred stock, par value (in dollars per share) | $ / shares             $ 0.00001          
Number of shares issuable upon conversion of preferred stock             224,663          
Conversion price per share | $ / shares             $ 75.6          
Net proceeds from warrant exercises | $             $ 17,500,000          
Proceeds from exercise of warrants | $             $ 19,400,000          
2023 Tranche B Preferred Warrants | Series E-4 preferred stock | September 2023 Private Placement                        
STOCKHOLDERS' EQUITY                        
Warrants issued to purchase shares               1,715        
2024 Tranche A Warrants                        
STOCKHOLDERS' EQUITY                        
Warrants issued to purchase shares                 114,773      
Exercise price of warrants (in dollars per share) | $ / shares             $ 75.6   $ 75.6      
Number of Days following the Announcement of Prescription Drug Use Fee Act Goal By FDA | D             10          
2024 Tranche B Warrants                        
STOCKHOLDERS' EQUITY                        
Warrants issued to purchase shares                 139,877      
Exercise price of warrants (in dollars per share) | $ / shares             $ 120   $ 120      
Number of days following the date of the Company's public announcement of its receipt of written approval from the FDA | D             10          
2024 Tranche C Warrants                        
STOCKHOLDERS' EQUITY                        
Warrants issued to purchase shares                 72,663      
Exercise price of warrants (in dollars per share) | $ / shares             $ 165   $ 165      
Number of days following the announcement of quarterly gross revenue from sales of iopofosine I 131. | D             10          
Threshold amount of quarterly gross revenues trigger for expiry of warrants | $             $ 10,000,000          
2025 Representative Warrants                        
STOCKHOLDERS' EQUITY                        
Warrants term                 5 years      
Warrants issued to purchase shares   82,800             82,800      
Exercise price of warrants (in dollars per share) | $ / shares                 $ 7.75      
July 2024 Warrants                        
STOCKHOLDERS' EQUITY                        
Warrant liability | $                 $ 180,000 $ 1,200,000